PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Cut to $28.00 by Analysts at Piper Sandler

Posted by Jeff Wilder on Feb 26th, 2026

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) had its price target decreased by research analysts at Piper Sandler from $50.00 to $28.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 27.00% from the company’s current price.

PRCT has been the topic of several other research reports. Oppenheimer cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Thursday. Bank of America lowered PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $38.00 to $20.00 in a research report on Thursday. UBS Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price target on the stock. Wall Street Zen raised shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Morgan Stanley cut their price objective on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research note on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.70.

View Our Latest Report on PROCEPT BioRobotics

PROCEPT BioRobotics Price Performance

PRCT traded down $5.79 during trading on Thursday, reaching $22.05. 4,546,793 shares of the company were exchanged, compared to its average volume of 1,303,223. The company’s 50-day moving average is $30.37 and its two-hundred day moving average is $33.71. PROCEPT BioRobotics has a 12-month low of $19.35 and a 12-month high of $68.70. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -14.21 and a beta of 0.99. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) earnings per share. Research analysts forecast that PROCEPT BioRobotics will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of institutional investors have recently bought and sold shares of PRCT. AQR Capital Management LLC lifted its position in PROCEPT BioRobotics by 7.3% during the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after buying an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of PROCEPT BioRobotics by 9.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after acquiring an additional 13,767 shares in the last quarter. Intech Investment Management LLC lifted its position in PROCEPT BioRobotics by 54.4% during the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after acquiring an additional 10,002 shares during the period. CWM LLC boosted its stake in PROCEPT BioRobotics by 40.7% during the second quarter. CWM LLC now owns 1,228 shares of the company’s stock worth $71,000 after acquiring an additional 355 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in PROCEPT BioRobotics by 1,262.5% in the second quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after purchasing an additional 1,010 shares during the period. 89.46% of the stock is owned by institutional investors.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

Positive Sentiment: Management issued FY‑2026 revenue guidance of $390M–$410M, modestly above consensus, suggesting longer‑term growth expectations remain intact. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
Positive Sentiment: The company hosted a 2026 Investor Day to lay out its multi‑year financial outlook and strategic plan, which could support confidence if management delivers execution and cadence at upcoming milestones. PROCEPT BioRobotics Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
Neutral Sentiment: Independent bullish write‑ups and analyst previews highlight the company’s market opportunity in urology and longer‑term upside scenarios, but these are speculative pending execution and near‑term results. PROCEPT BioRobotics Corporation (PRCT): A Bull Case Theory
Negative Sentiment: Q4 results missed across the board: EPS of ($0.53) vs. consensus ($0.32) and revenue of $76.38M vs. $93.7M consensus — the primary catalyst for the sell‑off. PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Lags Revenue Estimates
Negative Sentiment: Near‑term outlook weakened materially — Q1 2026 revenue guidance of $79M–$82M is far below the ~$93.7M consensus, indicating a slower start to 2026 and pressuring short‑term revenue visibility. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
Negative Sentiment: Analysts responded with downgrades — Bank of America cut to “underperform” with a $20 PT and Oppenheimer trimmed to “market perform,” amplifying selling pressure. Finviz PRCT Quote Page (analyst actions)
Negative Sentiment: Coverage pieces and market writeups flagged the stock hitting a 52‑week low following the results and guidance update — a technical sign that momentum traders have turned bearish. PROCEPT BioRobotics Stock Hits 52-Week Low – Here’s Why

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.